[{"id":"95af92d3-7ef1-42bc-8075-503c2a4324fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03975387","created_at":"2021-01-18T19:33:08.305Z","updated_at":"2024-07-02T16:35:05.855Z","phase":"Phase 1/2","brief_title":"Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53","source_id_and_acronym":"NCT03975387","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASTX295"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-06"}]